Most solid tumours will prove fatal if they are not treated with surgery and/or radiotherapy and medical therapies. But evidence is building to show that treating the primary may raise the risk of metastatic spread. [more]
‘Survivorship’ is a rapidly growing field of research, as more cancer patients live longer, and require different types of support to get their lives back on track. Typically such research has been disconnected from clinical [more]
Precision medicine was meant to see the end of ‘maximum tolerated dose’ as the standard for introducing new drugs. It hasn’t happened, and many patients continue to suffer unnecessary toxicity from overtreatment, with health services [more]
Lung cancer kills more people in Europe than any other type of cancer, yet efforts to monitor and improve standards of treatment and care have lagged behind those of less fatal cancers, such as breast [more]
With studies showing that around half of all cancer patients use therapies that are not part of mainstream medicine, Cancer World Editor Alberto Costa explores some aspects of the discussion on what complementary and integrative [more]
Umberto Veronesi passed away on the 8th of November 2016, at the end of a career dedicated to fighting cancer. During his long and productive life he made significant contributions to improving cancer care and [more]
Evidence-based medicine is the cornerstone of medical practice, and yet clinicians are rarely offered training in the tricky business of finding, evaluating and making sense of the evidence they need. Anna Rouillard reports on an [more]
It makes no sense to perform clinical research that has no relevance to patient care, so why do we do it, and how can we stop? John Ioannidis ponders the problem and offers some suggestions. [more]
P Hadji, R E. Coleman, C Wilson et al. (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016, 27:379–90 Bisphosphonates should be considered as part [more]
Despite a rapid rise in cancer cases in low- and middle-income countries, many governments have been disastrously slow to turn their attention to planning and implementing cancer services, thanks in no small part to the [more]
Mortality data show that a precipitous rise in deaths from cutaneous melanoma in countries of northern Europe, Australia and north America, which started in the 1950s, may now be stabilising. Yet a paper published last [more]
The chances of surviving a childhood cancer have changed very little over the past two decades. Sophie Fessl talked to parents, doctors, regulators and researchers about what has to be done to address this disastrous [more]
Starting next year, trial sponsors can negotiate ethical approval in a member state of their choice, and have the same terms applied across all EU countries. Daniela Ovadia looks at the implications of the new regulation [more]